Upfront surgery or definitive radiotherapy for patients with p16-negative oropharyngeal squamous cell carcinoma. A GETTEC multicentric study.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
02 2021
Historique:
received: 08 01 2020
revised: 13 07 2020
accepted: 23 07 2020
pubmed: 3 10 2020
medline: 23 4 2021
entrez: 2 10 2020
Statut: ppublish

Résumé

Therapeutic management of oropharyngeal squamous cell carcinomas (OPSCC) is still debated. Since the role of HPV was demonstrated, few studies have focused on HPV-negative OPSCC. The aim of our study was to assess the impact of therapeutic strategy (surgical vs. non-surgical) on oncologic outcomes in patients with HPV-negative OPSCC. All p16-negative OPSCCs treated from 2009 to 2014 in 7 tertiary-care centers were included in this retrospective study and were classified according to the therapeutic strategy: surgical strategy (surgery ± adjuvant radiotherapy and chemotherapy) vs. non-surgical strategy (definitive radiotherapy ± chemotherapy). Patients not eligible for surgery (unresectable tumor, poor general-health status) were excluded. Univariate, multivariate and propensity score matching analyses were performed to compare overall (OS), disease-specific (DSS) and recurrence-free survival (RFS). Four hundred seventy-four (474) patients were included in the study (surgical group: 196; non-surgical group: 278). Five-year OS, DSS and RFS were 76.5, 81.3 and 61.3%, respectively, in the surgical group and 49.9, 61.8 and 43.4%, respectively, in the non-surgical group. The favorable impact of primary surgical treatment on oncologic outcomes was statistically significant after multivariate analysis. This effect was more marked for locally-advanced than for early-stage tumors. Propensity score matching analysis confirmed the prognostic impact of primary surgical treatment for RFS. Therapeutic strategy is an independent prognostic factor in patients with p16-negative OPSCC and primary surgical treatment is associated with improved OS, DSS and RFS. These results suggest that surgical strategy is a reliable option for advanced stage OPSCC.

Identifiants

pubmed: 33004271
pii: S0748-7983(20)30661-2
doi: 10.1016/j.ejso.2020.07.034
pii:
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

367-374

Informations de copyright

Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Dorian Culié (D)

University Institute of the Face and Neck, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France. Electronic address: dorian.culie@nice.unicancer.fr.

Julien Viotti (J)

Department of Statistics, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Anouchka Modesto (A)

Department of Radiotherapy, Cancer University Institute of Toulouse, Toulouse, France.

Renaud Schiappa (R)

Department of Statistics, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Emmanuel Chamorey (E)

Department of Statistics, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Olivier Dassonville (O)

University Institute of the Face and Neck, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Gilles Poissonnet (G)

University Institute of the Face and Neck, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Bruno Guelfucci (B)

Department of Otorhinolaryngology and Head and Neck Surgery, Sainte Musse Hospital, Toulon, France.

Alain Bizeau (A)

Department of Otorhinolaryngology and Head and Neck Surgery, Sainte Musse Hospital, Toulon, France.

Sebastien Vergez (S)

Department of Otorhinolaryngology and Head and Neck Surgery, Cancer University Institute of Toulouse, Toulouse, France.

Agnes Dupret-Bories (A)

Department of Otorhinolaryngology and Head and Neck Surgery, Cancer University Institute of Toulouse, Toulouse, France.

Renaud Garrel (R)

Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital of Montpellier, Montpellier, France.

Nicolas Fakhry (N)

Department of Otorhinolaryngology and Head and Neck Surgery, Public Assistance - Hospitals of Marseille, Marseille, France.

Laure Santini (L)

Department of Otorhinolaryngology and Head and Neck Surgery, Public Assistance - Hospitals of Marseille, Marseille, France.

Benjamin Lallemant (B)

Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital of Nîmes, Nîmes, France.

Guillaume Chambon (G)

Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital of Nîmes, Nîmes, France.

Anne Sudaka (A)

Department of Pathology, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Frederic Peyrade (F)

Department of Medical Oncology, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Esma Saada-Bouzid (E)

Department of Medical Oncology, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Karen Benezery (K)

Department of Radiotherapy, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Florence Jourdan-Soulier (F)

Department of Pathology, Sainte Musse Hospital, Toulon, France.

Françoise Chapel (F)

Department of Pathology, Sainte Musse Hospital, Toulon, France.

Anne Sophie Ramay (AS)

Department of Pathology, University Hospital of Nîmes, Nîmes, France.

Pascal Roger (P)

Department of Pathology, University Hospital of Nîmes, Nîmes, France.

Thibault Galissier (T)

Department of Pathology, Cancer University Institute of Toulouse, Toulouse, France.

Valérie Coste (V)

Department of Pathology, University Hospital of Montpellier, Montpellier, France.

Aicha Ben Lakdar (A)

Department of Pathology, Gustave Roussy Institute, Villejuif, France.

Joanne Guerlain (J)

Department of Otorhinolaryngology and Head and Neck Surgery, Gustave Roussy Institute, Villejuif, France.

Stephane Temam (S)

Department of Otorhinolaryngology and Head and Neck Surgery, Gustave Roussy Institute, Villejuif, France.

Haitham Mirghani (H)

Department of Otorhinolaryngology and Head and Neck Surgery, Gustave Roussy Institute, Villejuif, France.

Phillipe Gorphe (P)

Department of Otorhinolaryngology and Head and Neck Surgery, Gustave Roussy Institute, Villejuif, France.

Alexandre Bozec (A)

University Institute of the Face and Neck, Antoine Lacassagne Centre, Côte d'Azur University, Nice, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH